Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236702 · ClinicalTrials.gov registry record
Kappa Opioid Receptor Imaging in Depression (KOR Depression)
A clinical trial, sponsored by NYU Langone Health.
- Terminated
- Registry status
- 15
- Enrollment target
NCT02236702: Clinical Trial study, sponsored by NYU Langone Health.
NCT02236702 is a clinical trial that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02236702 was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to use positron emission tomography (PET) imaging to measure the activity of the kappa opioid receptor (KOR) in the brains of depressed and non-depressed individuals.
Primary Outcome
To use the KOR radioligand \[11C\]LY2795050 and PET to examine the relation between KOR availability in the ventral striatum and amygdala, and the full dimensional spectrum of threat and loss symptomatology, and reward responsiveness.
Interventions
- OTHER Positron Emission Tomography (PET) imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-02 |
Why NCT02236702 stopped before completion
NCT02236702 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Positron Emission Tomography (PET) imaging is the first listed.
NCT02236702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02236702 about?
NCT02236702 is a clinical study titled "Kappa Opioid Receptor Imaging in Depression (KOR Depression)". The purpose of this study is to use positron emission tomography (PET) imaging to measure the activity of the kappa opioid receptor (KOR) in the brains of depressed and non-depressed individuals.
What is the current status of trial NCT02236702?
This trial is currently terminated. The enrollment target is 15 participants. The study started on 2014-08. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02236702?
The interventions under investigation include: Positron Emission Tomography (PET) imaging (OTHER).
Who is sponsoring clinical trial NCT02236702?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia